Precision Medicine and Health Consortium (PMHC)
The Precision Medicine and Health Consortium capitalizes on the expertise within the scientific community, health systems, payor industry and others to make novel discoveries and therapeutic advances in precision medicine, and translate these to improve healthcare.
The PMHC joins together faculty with a common purpose and connects faculty with expertise in precision medicine to address health problems using an interdisciplinary approach. It is our belief that a interdisciplinary group will more quickly advance research, educational, and outreach activities.
Members of the PMHC also bridge the gap between genetic research discoveries and application in patient care. Precision Medicine is a national priority and this group strives to keep on the forefront of this evolving field.
The ASCO Post highlighted the extraordinary response to targeted therapy of a patient with an adult medulloblastoma brain tumor, the first such report in the first-line setting using hedgehog inhibitor vismodegib (Erivedge). The case report was published in
"Minnesota Precision Medicine Collaborative: Transforming health and advancing equity," was named one of eight U of M Grand Challenges Research collaboration grants to advance the research goals of the TC Campus Strategic Plan over the next ten years.
Development of a clinical precision medicine program in ovarian cancer as a paradigm for 21st century tailored health care solutions
In a recent survey designed to measure public attitudes about the Precision Medicine Initiative (PMI) Cohort Program, a majority of respondents expressed willingness to participate in the nationwide research effort.
The research effort that aims to engage 1 million or more U.S.
The UMN College of Education and Human Development will be hosting a 3 day conference on precision healthcare and childrens mental health, October 5-7. More information here.
This year's Conference had 300 attendees and 150 registrants were genotyped.
The National Institutes of Health (NIH) has awarded the first-ever grant dedicated to laying the policy groundwork needed to translate genomic medicine into clinical application. Professor Susan M.